Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM)

Assessment Of A Novel Metabolic Imaging Modalities As A Predictor Of Therapeutic Efficacy In Glioblastoma (GBM)

The goal of this study is to evaluate the prognostic capacity of DMI in a trial assessing the efficacy of adding BPM31510, a lipid nano dispersion of CoQ10 to standard treatment of Glioblastoma (GBM).

Inclusion Criteria:

• Any participant that consents to entry into the Phase II BPM31510 parent study (BPM31510IV-11)
• Women of childbearing potential must have a negative pregnancy test
• Ability to understand and the willingness to provide written informed consent.

Exclusion Criteria:

• Refuse to have an IV
• Allergy to MRI contrasts
• Diabetic patients who are taking insulin